Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.2337/dc09-1471. Epub 2010 Jan 26.
Laura C Lovato, Denise G Simons-Morton, David M Kendall, Rodica Pop-Busui, Robert M Cohen, Denise E Bonds, Vivian A Fonseca, Faramarz Ismail-Beigi, Mary Ann Banerji, Alan Failor, Bruce Hamilton
Affiliations
- PMID: 20103550
- PMCID: PMC2845012
- DOI: 10.2337/dc09-1471
Randomized Controlled Trial
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Jorge Calles-Escandón et al. Diabetes Care. 2010 Apr.
Abstract
Objective: To determine if baseline subgroups in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial can be identified for whom intensive compared with standard glycemia treatment had different effects on all-cause mortality.
Research design and methods: Exploratory post hoc intention-to-treat comparisons were made between intensive and standard glycemia groups on all-cause mortality by subgroups defined by baseline characteristics.
Results: There were few significant interactions between baseline characteristics and effects of intensive versus standard glycemia treatment on mortality: self-reported history of neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41-2.69) versus no history of neuropathy (0.99, 0.79-1.26; P value for interaction 0.0008), higher A1C (A1C >8.5%: HR 1.64, 95% CI 1.22-2.22; A1C 7.5-8.4%: 1.00, 0.75-1.34; A1C <7.5%: 1.00, 0.67-1.50; P value for interaction 0.04), and aspirin use (HR 1.45, 95% CI 1.13-1.85, compared with 0.96, 0.72-1.27, in nonusers; P value for interaction 0.03).
Conclusions: We found a remarkable similarity of effect from intensive compared with standard glycemia treatment on mortality across most baseline subgroups. No differential effect was found in subgroups defined by variables anticipated to have an interaction: age, duration of diabetes, and previous history of cardiovascular disease. The three baseline characteristics that defined subgroups for which there was a differential effect on mortality may help identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for glycemic control. Further research is warranted.
Figures
Figure 1
Demographic characteristics and medical history. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within demographic and medical history subgroups, adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
Figure 2
Medication and laboratory tests. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within the medication and laboratory tests subgroups adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
Figure 3
A1C and all-cause mortality. Spline curves displaying the log of the HR for all-cause mortality by treatment and baseline A1C are shown. All HRs are with respect to standard glycemia with baseline A1C of 7.0. The bold line represents the intensive treatment group, the finer line the standard group, and the colored lines the 95% CIs.
Comment in
- Neuropathy: the crystal ball for cardiovascular disease?
Vinik AI, Maser RE, Ziegler D. Vinik AI, et al. Diabetes Care. 2010 Jul;33(7):1688-90. doi: 10.2337/dc10-0745. Diabetes Care. 2010. PMID: 20587730 Free PMC article. No abstract available.
Similar articles
- Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr. Margolis KL, et al. Diabetes Care. 2014 Jun;37(6):1721-8. doi: 10.2337/dc13-2334. Epub 2014 Mar 4. Diabetes Care. 2014. PMID: 24595629 Free PMC article. Clinical Trial. - Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman WC. Beddhu S, et al. J Am Heart Assoc. 2018 Sep 18;7(18):e009326. doi: 10.1161/JAHA.118.009326. J Am Heart Assoc. 2018. PMID: 30371182 Free PMC article. Clinical Trial. - Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.
Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; ACCORD Investigators. Miller ME, et al. Diabetes Care. 2014;37(3):634-43. doi: 10.2337/dc13-1545. Epub 2013 Oct 29. Diabetes Care. 2014. PMID: 24170759 Free PMC article. Clinical Trial. - Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Seidu S, et al. Diabet Med. 2016 Mar;33(3):280-9. doi: 10.1111/dme.12885. Epub 2015 Sep 8. Diabet Med. 2016. PMID: 26282461 Review. - Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD.
Hoogwerf BJ; Action to Control Cardiovascular Risk in; Diabetes Study Group. Hoogwerf BJ, et al. Cleve Clin J Med. 2008 Oct;75(10):729-37. doi: 10.3949/ccjm.75.10.729. Cleve Clin J Med. 2008. PMID: 18939389 Review.
Cited by
- Genetic Factors Associated with the Development of Neuropathy in Type 2 Diabetes.
Tordai DZ, Hajdú N, Rácz R, Istenes I, Békeffy M, Vági OE, Kempler M, Körei AE, Tóbiás B, Illés A, Pikó H, Kósa JP, Árvai K, Papp M, Lakatos PA, Kempler P, Putz Z. Tordai DZ, et al. Int J Mol Sci. 2024 Feb 2;25(3):1815. doi: 10.3390/ijms25031815. Int J Mol Sci. 2024. PMID: 38339094 Free PMC article. - What have clinical trials taught us about brain health?
Lee KJ, Bae HJ. Lee KJ, et al. Cereb Circ Cogn Behav. 2023 Dec 28;6:100199. doi: 10.1016/j.cccb.2023.100199. eCollection 2024. Cereb Circ Cogn Behav. 2023. PMID: 38235315 Free PMC article. - Changes in body mass index and waist circumference and heart failure in type 2 diabetes mellitus.
Zhou Y, Chai X, Yang G, Sun X, Xing Z. Zhou Y, et al. Front Endocrinol (Lausanne). 2023 Dec 21;14:1305839. doi: 10.3389/fendo.2023.1305839. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38179309 Free PMC article. Clinical Trial.
References
- Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163–169 - PubMed
- Andersson DK, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995;18:1534–1543 - PubMed
- Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992;41:731–735 - PubMed
- Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139 - PubMed
- Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical